Been digging into the diabetes treatment space lately and honestly, the pullback we've seen in these healthcare stocks over the past few months looks pretty interesting from a long-term perspective.

So here's what caught my attention: back in 2022, the diabetes market was valued around $89 billion. Fast forward to now and analysts are projecting this could hit $223 billion by 2032. That's serious growth potential, especially considering how the GLP-1 weight-loss drug trend actually boosted demand for glucose monitors instead of cannibalizing it like everyone feared.

Let me break down three diabetes stocks worth watching right now:

Tandem Diabetes Care (TNDM) has been getting some solid analyst attention. Citi upgraded them to buy back in May, specifically bullish on their new Mobi insulin delivery system. What's interesting is their sales grew 12% last quarter, and management is guiding for 12% growth this year, which analysts think is actually conservative. The potential integration with Dexcom's products could be a real catalyst here. The stock's showing strong momentum too - relative strength score of 96 suggests it's been outperforming significantly.

Insulет Corporation (PODD) is another name on my radar. Redburn Atlantic (Rothschild's research arm) just initiated coverage with a buy rating. Their research showed 76% of endocrinologists would likely recommend Insulet's Omnipod 5 pump, and they're expecting the insulin pump market to grow at 13% annually through 2028. Operating income jumped 52% last quarter, which is pretty solid execution.

Then there's Dexcom (DXCM), the market leader in continuous glucose monitors. Wells Fargo surveyed 50 endocrinologists and expects Dexcom's market share to edge up from 55% in 2023 to 58% by 2025. RBC Capital thinks they're positioned to be one of the fastest-growing large-cap MedTech companies. Their last quarter numbers were impressive - net income nearly tripled to $146.4 million, revenue up 24% year-over-year to $921 million.

The diabetes stocks space has definitely cooled off from its peaks, but given the market tailwinds and solid fundamentals across these companies, the recent pullback might be setting up an interesting entry point for patient investors. Worth keeping on your watchlist if you're looking at healthcare exposure.